Search trials – HealthDB

Активни:

Намерени 4,781 изпитвания Стр. 225 от 240

Active (not recruiting) Phase 2

A Study of SmartFlow Magnetic Resonance (MR) Compatible Ventricular Cannula for Administering Eladocagene Exuparvovec to Pediatric Participants

AADC Deficiency

This study will have a trial phase, extension phase, and a long-term extension phase. The primary objectives of the trial phase are to assess the pharmacodynamics (PD) of eladocagene exuparvovec treatment by evaluation of homovanillic acid (HVA) levels and to assess the safety of the SmartFlow® magnetic resonance (MR) Compatible Ventricular Cannula for administering eladocagene exuparvovec to pediatric participants with aromatic L-amino acid decarboxylase (AADC) deficiency. The extension phase is designed to capture additional clinical information for eladocagene exuparvovec through study evaluations, changes in motor development, AADC-specific symptoms, and other PD measures. The long-term extension phase is designed to capture long-term safety and efficacy data from participants treated with eladocagene exuparvovec.

Начало: 12.05.2021 Край: 30.04.2028 Възраст: 1–17 г.

Israel, Taiwan, United States PTC Therapeutics NCT04903288

Active (not recruiting)

Safety & Effectiveness Evaluation of Seraph 100 in Treatment of Pts With COVID-19

COVID-19

Safety and Effectiveness Evaluation of Seraph 100 Microbind Affinity Blood Filter (Seraph 100) in the treatment of patients with COVID-19

Начало: 04.05.2021 Край: 30.06.2027 Възраст: 18–90 г.

Germany, Spain ExThera Medical Corporation NCT04547257

Active (not recruiting) Phase 2

Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial

Hematopoietic and Lymphatic System Neoplasm Recurrent Ependymoma Recurrent Ewing Sarcoma Recurrent Hepatoblastoma +34

This phase II pediatric MATCH treatment trial studies how well selpercatinib works in treating patients with solid tumors that may have spread from where they first started to nearby tissue, lymph nodes, or distant parts of the body (advanced), lymphomas, or histiocytic disorders that have activating RET gene alterations. Selpercatinib may block the growth of cancer cells that have specific genetic changes in an important signaling pathway (called the RET pathway) and may reduce tumor size.

Начало: 03.05.2021 Край: 30.06.2026 Възраст: 12–21 г. Treatment

Australia, Puerto Rico, United States National Cancer Institute (NCI) NCT04320888

Active (not recruiting) Early Phase 1

AB154 Combined With AB122 for Recurrent Glioblastoma

Glioblastoma

This is a phase 0/I exploratory study. Patients at first or second recurrence of glioblastoma will be enrolled. The study will be divided into two cohorts: Cohort A (safety cohort) and Cohort B (surgical patient cohort). Cohort A: Eligible patients will be sequentially enrolled to receive intravenous domvanalimab combined with zimberelimab (N=6). Domvanalimab will be given at a dose of 10 mg/kg and zimberelimab will be given at a dose of 240 mg (flat). The dosing was determined in a separate study in solid tumors; this cohort will confirm the safety of the dosing schedule in patients with brain tumors. Cohort B: Expansion surgical cohort. The purpose of cohort B is to provide an additional safety evaluation of domvanalimab + zimberelimab as well as tissue and blood for exploratory ancillary studies investigating the effects of domvanalimab + zimberelimab in the tumor and tumor microenvironment. A total of 46 patients will be enrolled in this cohort.

Начало: 21.04.2021 Край: 31.12.2026 Възраст: от 18 г.

United States Yale University NCT04656535

Active (not recruiting) Phase 2

The Effect of Acupuncture on Cancer-Related Cognitive Difficulties

Breast Cancer

The purpose of this study is to test whether acupuncture can improve cognitive difficulties and insomnia in survivors of breast cancer. Researchers will compare the effects of real acupuncture with those of placebo acupuncture and wait-list acupuncture. This study will also look at insomnia's link to cognitive difficulties. All study participants (receiving real acupuncture, placebo acupuncture, or wait-list acupuncture) will complete study questionnaires and/or have cognitive testing at Weeks 0, 4, 10, 14 and 26. After the Week 26 visit, your participation in this study will end. If you are assigned to receive placebo acupuncture or wait-list acupuncture, you will have the option of receiving up to 10 real acupuncture treatments within the six months after the study finishes.

Начало: 06.04.2021 Край: 01.04.2027 Възраст: от 18 г.

United States Memorial Sloan Kettering Cancer Center NCT04837820

Active (not recruiting)

Single Palatal Temporary Anchorage Device for Anterior Open Bite

Anterior Openbite

Participants are orthodontic patients with anterior open bite (AOB) malocclusion. These patients will be treated by molar intrusion achieved using one of two interventions, either orthodontic fixed appliances incorporating a single palatal Temporary Anchorage Device (TAD) or orthodontic fixed appliances incorporating two buccal TADs

Начало: 01.04.2021 Край: 30.12.2026 Възраст: 12–40 г.

United Kingdom University of Dundee NCT04419805

Active (not recruiting)

Dilated Cardiomyopathy-Cardiac Magnetic Resonance (DCM-CMR) Ancillary Study

Dilated Cardiomyopathy

The Dilated Cardiomyopathy-Cardiac Magnetic Resonance (DCM-CMR) Study is an ancillary study from the parent study, DCM Precision Medicine Study. The rationale for the DCM-CMR study is to leverage cardiac magnetic resonance (CMR) imaging to detect earliest findings of DCM in the at-risk family members enrolled into the parent study.

Начало: 01.04.2021 Край: 01.12.2026 Възраст: от 18 г.

United States Ohio State University NCT04638621

Active (not recruiting) Phase 2

Testosterone Replacement in Male Cancer Survivors With Fatigue and Low Testosterone

Hypogonadism, Male Fatigue Syndrome, Chronic

The overall goal of this study is to evaluate the effect of a testosterone drug called Depo-Testosterone (or 'testosterone cypionate'), an FDA-approved drug for improving fatigue, sexual function, quality of life, body composition, muscle strength, and physical activity in young cancer survivors who report fatigue and have low testosterone. Main hypothesis is that Testosterone administration in young male cancer survivors who are in remission for at least 1 year, report cancer-related fatigue and have symptomatic testosterone deficiency will be associated with greater improvements in fatigue scores compared with placebo.

Начало: 22.03.2021 Край: 30.01.2027 Възраст: 18–54 г.

United States Seattle Institute for Biomedical and Clinical Research NCT04049331

Active (not recruiting)

A Follow-Up Study of Straight and Tapered Dental Implants in the Front Upper Jaw

Tooth Loss in the Anterior Maxilla Partial Edentulism of the Maxilla

This prospective study aims to evaluate 5-year clinical, radiographic, and patient-reported outcomes of implant-supported crowns and bridges placed on Neoss implants (ProActive Straight and Tapered) in the anterior maxilla (region 13 - 23). The study is conducted at Brånemarkkliniken, Public Dental Service, Västra Götalandsregionen, Sweden. While the treatment involves established methods and CE-marked devices, long-term data for this specific indication are limited.

Начало: 21.03.2021 Край: 31.07.2030 Възраст: от 18 г.

Sweden Branemarkkliniken NCT07544706

Active (not recruiting)

LUX-Dx TRENDS Evaluates Diagnostics Sensors in Heart Failure Patients Receiving Boston Scientific's Investigational ICM System.

Heart Failure

The primary objective of this study is to collect sensor data from insertable cardiac monitor systems.

Начало: 20.03.2021 Край: 01.06.2026 Възраст: от 18 г.

United States Boston Scientific Corporation NCT04790344

Active (not recruiting) Phase 2

Lenvatinib and Pembrolizumab in People With Advanced Soft Tissue Sarcoma

Advanced Sarcoma

The purpose of this study is to find out whether combining the study drugs, lenvatinib and pembrolizumab, is a safe and effective treatment for metastatic soft tissue sarcomas that cannot be removed with surgery.

Начало: 18.03.2021 Край: 01.03.2027 Възраст: от 18 г.

United States Memorial Sloan Kettering Cancer Center NCT04784247

Active (not recruiting) Phase 3

Study of LOXO-305 (Pirtobrutinib) Versus Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma

This is a study for patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have previously received treatment with at least a BTK inhibitor. The main purpose is to compare LOXO-305 to idelalisib plus rituximab or bendamustine plus rituximab. Participation could last up to four years, and possibly longer, if the disease does not progress.

Начало: 09.03.2021 Край: 01.05.2027 Възраст: от 18 г. Treatment

Australia, Austria, Belgium +21 Loxo Oncology, Inc. NCT04666038

Active (not recruiting) Phase 2

Romosozumab to Improve Bone Mineral Density and Architecture in Chronic SCI

Spinal Cord Injury (=3 Years) Sublesional Bone Loss Secondary to SCI

Treatment for sublesional bone loss (osteoporosis) in persons with chronic, motor-complete spinal cord injury (SCI) has been limited and unsuccessful to date. Romosozumab, a sclerostin antagonist, has potential to increase bone formation (anabolic) and decrease bone resorption (anti-catabolic) in persons with chronic SCI. Conventional anti-resorptive therapy alone would not be anticipated to reverse sublesional bone loss in a timely manner because the skeleton below the level of lesion in chronic SCI is assumed to be in a low turnover state. However, because there is a high likelihood that the bone accrued while on romosozumab will be lost once discontinued, denosumab, an anti-resorptive agent, will be administered after treatment with romosozumab, to maintain or, possibly, to continue to increase, bone mineral density (BMD). The purpose of this study is to address the gap in the treatment of osteoporosis in individuals with chronic SCI by partially restoring BMD with romosozumab treatment for 12 months and then to maintain, or further increase, BMD with denosumab treatment for 12 months. A two group, randomized, double-blind, placebo-controlled clinical trial will be conducted in 39 participants who have chronic (\>3 years), motor-complete or incomplete SCI and areal BMD (aBMD) values at the distal femur of at the distal femur \

Начало: 01.03.2021 Край: 01.03.2027 Възраст: 18–65 г.

United States VA Office of Research and Development NCT04232657

Active (not recruiting) Phase 2

Study of AZD2811 + Durvalumab in ES-SCLC

Small-Cell Lung Cancer

A Phase II Multicenter, Open-Label, Single Arm Study to Determine the Efficacy, Safety and Tolerability of AZD2811 and Durvalumab Combination as Maintenance Therapy After Induction with Platinum-Based Chemotherapy Combined with Durvalumab, for the First-Line Treatment of Patients with Extensive Stage Small-Cell Lung Cancer.

Начало: 23.02.2021 Край: 01.12.2026 Възраст: 18–130 г.

Poland, South Korea, Spain +1 AstraZeneca NCT04745689

Active (not recruiting) Phase 2

Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer

Non Small Cell Lung Cancer Nonsquamous Non Small Cell Lung Cancer Squamous Non Small Cell Lung Cancer Lung Cancer

This is a phase 2 study to evaluate zimberelimab (AB122) combined with domvanalimab (AB154) in front-line, PD-L1-high, locally advanced or metastatic Non-Small Cell Lung Cancer (NSCLC).

Начало: 08.02.2021 Край: 01.05.2027 Възраст: от 18 г.

Hong Kong, Malaysia, Philippines +7 Arcus Biosciences, Inc. NCT04736173

Active (not recruiting) Phase 2

Niraparib and Dostarlimab for the Treatment of Small Cell Lung Cancer and Other High-Grade Neuroendocrine Carcinomas

Lung Small Cell Carcinoma Neuroendocrine Carcinoma Stage III Lung Cancer AJCC v8 Stage IIIA Lung Cancer AJCC v8 +2

This phase II trial studies the effect of niraparib and dostarlimab in treating small cell lung cancer and other high-grade neuroendocrine carcinomas. Niraparib is an inhibitor of PARP, an enzyme that helps repair deoxyribonucleic acid (DNA) when it becomes damaged. Blocking PARP may help keep cancer cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy. Immunotherapy with monoclonal antibodies, such as dostarlimab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving niraparib and dostarlimab may help to control the diseases.

Начало: 01.02.2021 Край: 30.04.2027 Възраст: от 18 г.

United States M.D. Anderson Cancer Center NCT04701307

Active (not recruiting)

Feasibility of Home-based tES for Older Adults at Risk of Falling

Aging Accidental Falls

In this project, the investigators propose to demonstrate the feasibility of remotely-monitored, caregiver (or spouse)-administered, home-based tES (transcranial electrical stimulation) intervention to improve mobility in ambulatory older adults with recent falls. This is a four-phase feasibility study in older, ambulatory adult participants at risk of falling due to a loss of balance (participant faller, PF) together with a willing and able participant administrator (PA) that is available during weekdays to administer tES to the PF. Phase 1 is focused on the development and refinement of our training materials for home-based tDCS (transcranial direct current stimulation) for PF/PA pairs. The objectives of this phase: 1. Identify areas of confusion and challenges for older adults. 2. Refine our training materials to accompany the home-based tDCS system. In Phase 2, the investigators will complete a pilot trial in 12 PF/PA pairs to assess the feasibility of deploying home-based tES in larger clinical trials, and to prepare for the development and implementation of such trials. The objectives of this phase: 1. Determine the mean/range number of visits needed for in-person training. 2. Compliance and retention with the study protocol. 3. Safety/side effects of home-based tES, as compared to previously established laboratory-based tES data. The investigators hypothesize that adult PAs are able to successfully administer home-based tES to PFs. The investigators also expect that PF/PA pairs will exhibit excellent adherence to the intervention and that the prevalence and severity of reported tDCS side-effects will be similar to that observed in previous laboratory-based studies. In Phase 3, the investigators will complete a pilot trial in up to 18 PF/PA pairs; i.e., those who have previously successfully completed either Phase 1 or Phase 2. The study objectives/aims for Phase 3 are: 1. Further explore compliance and retention with the study protocol over a longer time period 2. Identify safety/side effects of home-based tES over a longer time-period as compared to previously established laboratory-based tDCS interventions. In Phase 3, the investigators hypothesize that adult PA's who have previously demonstrated the ability to successfully administer tES at home, will retain competence and compliance with administration over a longer period, up to 1 year. In Phase 4, we will complete a pilot trial in up to 18 PF/PA teams; those who have previously successfully completed Phase 3. The study objective/aims for Phase 4 will be to: 1. Identify Safety, effectiveness and adherence to home-based tES over longer period of time as compared to previously established laboratory-based tES interventions. 2. Further explore the proof of Concept for the home-based tES interventions In Phase 4 we hypothesize that adult PA's who have previously demonstrated the ability to successfully administer tES at home, will adhere with the study protocol over a longer period of time, up to 3 years.

Начало: 25.01.2021 Край: 30.12.2027 Възраст: от 60 г.

United States Hebrew SeniorLife NCT04732533

Active (not recruiting) Phase 2

Cobimetinib in Newly Diagnosed or HMA-treated CMML Patients With RAS Pathway Mutations

Chronic Myelomonocytic Leukemia (CMML)

This is an open-label, nonrandomized phase 2 trial to assess the efficacy of cobimetinib in RAS pathway activated CMML. All eligible patients will be treated daily with cobimetinib in 28-day cycles. Cobimetinib will be administered for three weeks followed by a one week break prior to the start of the following cycle. Patients will remain on study therapy until treatment discontinuation criteria is met.

Начало: 12.01.2021 Край: 01.08.2026 Възраст: от 18 г.

United States University of Utah NCT04409639

Active (not recruiting)

Prolonged Cardiac ECG Patch Versus Conventional Holter For Detecting Atrial Fibrillation After Cerebral Ischemic Event

Stroke Atrial Fibrillation

The aim of this study is to compare the diagnostic yield of water-resistant, wireless 7-day cardiac ECG patch versus conventional 24-hour Holter recording in detecting paroxysmal atrial fibrillation in patients admitted with acute ischemic stroke or transient ischemic attack of undetermined etiology after completion of a standard clinical stroke workup.

Начало: 12.01.2021 Край: 22.08.2027 Възраст: от 18 г.

Malaysia Sarawak General Hospital NCT05082467

Active (not recruiting)

Psychological Response and Readiness Associated With OCD of the Knee

Osteochondritis Dissecans Knee Psychological Stress

This study primarily aims to determine whether patients diagnosed with osteochondritis dissecans (OCD) of the knee experience psychological stress due to their diagnosis and treatment plan. Secondarily, this study aims to determine whether knee OCD patients experience a change in stress and depression as they progress through their standard-of-care treatment plan, and whether they have impaired psychological readiness for return to sport.

Начало: 04.01.2021 Край: 31.12.2026 Възраст: 11–19 г.

United States Boston Children's Hospital NCT04649905

1 … 223 224 225 226 227 … 240